

CURRICULUM VITAE

J. DAVID PORT, Ph.D.
PROFESSOR (TENURED)
MEDICINE/CARDIOLOGY AND PHARMACOLOGY
MEMBER, RNA BIOSCIENCES INITIATIVE
CU-CVI – SENIOR SCIENTIST

BUSINESS ADDRESS:

University of Colorado Anschutz Medical Campus
Departments of Medicine, Division of Cardiology and
Department of Pharmacology
Campus Box B139
12700 East 19th Avenue, Rm. 8001
Aurora, CO 80045
Tel: 303-724-5438
e-mail: david.port@ucdenver.edu

EDUCATION

1991 Post-Doctoral Fellowship, Pharmacology, SUNY Stony Brook SOM, Stony Brook, NY

1989 Ph.D. in Pharmacology, University of Utah SOM, Salt Lake City, UT

1979 B.S. in Biology, University of Utah, Salt Lake City, UT

PROFESSIONAL EXPERIENCE

2025- **Professor Emeritus**, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO

2005-2025 Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO

1998-2005 Associate Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO.
Tenure (2001)

1991-1998 Assistant Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO

1979-1985 Technical Director of Research, Department of Anesthesiology, University of Utah, School of Medicine, Salt Lake City, UT

AWARDS AND HONORS

- 2001 University of Colorado Health Sciences Center, Department of Medicine “Ph.D. Research and Teaching Award”
- 2001 University of Colorado Health Sciences Center, Department of Pharmacology “Teaching Award”
- 2009 Denver Business Journal, Finalist: Champions in Health Care
- 2010 CCTSI Leadership and Innovative Team Science (LITeS), Class of 2010
- 2011 Fellow, American Heart Association (FAHA), Basic Science Division
- 2011 University of Colorado School of Medicine, Department of Pharmacology “Faculty Excellence in Teaching Award”
- 2012 Outstanding Service and Leadership, American Heart Association, Denver Division
- 2015 Outstanding Dedication and Leadership, American Heart Association, Denver Division
- 2019 University of Colorado School of Medicine, Department of Pharmacology “Faculty Excellence in Teaching Award”

FINANCIAL SUPPORT, MAJOR GRANTS

NIH T32 Pre-Doctoral Fellowship, 1985-1988
University of Utah School of Medicine
Department of Pharmacology

American Heart Association, New York State Affiliate,
Post-Doctoral Fellowship
\$60,000 over 2 years (1990/91)
Project Title: Transmembrane signaling in idiopathic dilated cardiomyopathy: Models for study of G-protein biology.

Long Island Heart Association
Co-investigator, C.C. Malbon, Principal Investigator
Supplement to AHA Fellowship (1990-1991), \$30,000 over 2 years (supplies)
Project Title: Transmembrane signaling in idiopathic dilated cardiomyopathy: Models for study of G-protein biology.

Sepracor, Inc.
Co-investigator, M.R. Bristow, Principal Investigator
Contract: \$20,000 (1992)
Project Title: Effect of racemic and enantiomeric forms of atenolol and metoprolol on β -adrenergic receptor density in primary cultures of chick cardiomyocytes.

Boehringer Mannheim GmbH
Co-investigator, M.R. Bristow, Principal Investigator
Contract: \$160,000 over 2 years (1992-3)
Project Title: Further studies on the mechanism of action of carvedilol in human adrenergic receptor systems.

Colorado Heart Association
Principal Investigator
Beginning Grant-In-Aid
\$22,000 for 1 year (7/93 to 6/94)
Project Title: Regulation of beta-adrenergic receptor mRNA stability.

NIH
Principal Investigator
RO1 HL51239
\$350,000 (1-94 to 11-99)
Project Title: Regulation of beta-adrenergic receptor mRNA stability.

Colorado Heart Association
Principal Investigator
Beginning Grant-In-Aid
\$25,000 for 1 year (7/95 to 6/96)
Project Title: Regulation of human beta1-adrenergic receptor by phosphorylation.

University of Colorado Cancer Center
Principal Investigator
Research Project
\$13,500 for one year (9/96 to 8/97)
Project Title: Nucleotide binding specificity of mRNA protein, AUF1

Colorado Heart Association
Principal Investigator
Standard Grant-In-Aid
\$60,000 over 2 years (7/97 to 6/99)
Project Title: Role of AUF1 in the regulation of beta-adrenergic receptor mRNA stability.

Astra-Merck
Principal Investigator
Research Grant
\$49,740 over 1 year (1/98 to 12/98)
Project Title: Post-transcriptional regulation of β -adrenergic receptor genes.

NIH
1 S10 RR13955-01
Co-Investigator: J. Weil, Principal Investigator
Common Equipment Grant
\$287,700 over 1 year (4/99 to 3/00)
Project Title: Small animal echocardiography system.

American Heart Association, Desert/Mountain Affiliate
Standard Grant-In-Aid
Principal Investigator
\$79,928 over 2 years (7/99 to 6/01)
Title: Overexpression of the human beta1-adrenergic receptor in transgenic mice.

NIH
RO1 HL51239
Principal Investigator
\$778,847 (9/30/99-9/30/04)
Title: Regulation of beta-adrenergic receptor mRNA stability.

AstraZeneca Principal Investigator
Research Grant

\$75,000 (04/01 - 03/02)

Project Title: Effects of beta-blockade on the progression of heart failure in transgenic mice over-expressing the human beta1-adrenergic receptor.

NIH

RO1 AG15897

Douglas Seals, P.I., J.D. Port, co-investigator (12/01/04 – 11/30/06)

\$250,000 (direct costs to P.I.)

Title: Human aging and beta-adrenergic receptor modulation in thermogenesis.

RO1 HL048013

(M.R. Bristow, P.I.; J.D. Port, investigator) 12/03-11/07

NIH

\$1,906,205 (direct costs) to P.I.

Project Title: Genetic-adrenergic interactions in myocardial failure

NIH

T32 GM007635

(Boris Tabakoff, P.I., J.D. Port, co-P.I.) 07/04-06/09

\$1,459,912 (direct costs) to P.I.

Title: Predoctoral training program in pharmacology

NIH

RO1 HL51239R

Principal Investigator (07/01/04-6/31/11* NCE)

\$1,250,000 (direct costs)

Title: Regulation of beta-adrenergic receptor mRNA stability.

University of Colorado Technology Transfer Office

PoPg Grant

Principal Investigator (12/01/07 – 05/01/08)

\$24,925 (direct costs)

Title: microRNAs as therapeutic targets in heart failure

T32 (Nancy Zahniser, P.I., J.D. Port, co-P.I.) 07/09-06/14

NIH

\$1,500,000 (direct costs)

Title: Predoctoral training program in pharmacology

NIH

1P20HL101435-01 (C-TRIP) (04/01/10 – 03/31/13* NCE)

Co-Principal Investigators: Port JD, Buttrick P, Lowes B, and Wu C.

\$998,765 (direct costs)

Title: Using molecular pathology to predict response in heart failure

Sponsored Research Agreement

07/10 - 02/14

miRagen Therapeutics, Inc.

Principal Investigator

\$158,000

Title: Human Heart miR Array Analysis

University of Colorado School of Medicine

AEF Funding

11/11

Principal Investigator
\$50,000

T32 (Andrew Thorburn, P.I., J.D. Port, co-P.I.) 07/14 - 06/19
NIH

1,723,420 (direct costs)
Title: Predoctoral training program in pharmacology

3T32GM008730-17S1 (P.I., R. Sclafani,
J.D. Port. Co-investigator) 07/01/16 – 06/30/2017
NIH/NIGMS

\$75,242 (direct costs)
Rigor and Reproducibility in Biomedical Research Supplement
Training for PhD students in Molecular Biology and Pharmacology in Rigor and Reproducibility
Role: collaborator

CU Innovations
Intellectual Property Royalties 08/18
\$72,132 (from a total of \$961,758 distributed to CU administration and faculty)

NIH
T32 T32 GM007635
(M. Dell'Acqua, P.I., J.D. Port, co-P.I.) 07/19 - 06/24
\$1,353,664
Title: Predoctoral training program in pharmacology (parent grant)
Supports 7 pre-doctoral trainees per year

NIH
T32 T32 GM007635
(Dell'Acqua, P.I., J.D. Port, co-P.I.) 07/19 - 06/20
\$108,655
Title: Predoctoral training program in pharmacology INCLUDE Supplement
Supported 3 additional pre-doctoral trainees per year

NIH
T32 T32 GM007635
(M. Dell'Acqua, P.I., J.D. Port, co-P.I.) 07/20 - 06/21
\$108,655
Title: Predoctoral training program in pharmacology INCLUDE Supplement
Supported 3 additional pre-doctoral trainees per year

NIH
T32 T32 GM007635
(Dell'Acqua, P.I., J.D. Port, co-P.I.) 07/21 - 06/22
~\$111,960
Title: Predoctoral training program in pharmacology INCLUDE Supplement
Supported 3 additional pre-doctoral trainees per year

NIH
3T32GM136444-02S1 (MPI, R. Prykeris, J. Hesselberth, J.D. Port. Co-investigator)
7/01/21 – 06/30/2022

\$85,320 (total costs)

Training for enhanced mentoring for faculty in the Molecular Biology, and Cell Biology T32 programs

Role: Associated Program Director and mentor training implementor

NIH

T32 GM00763544S1

(Dell'Acqua, P.I., J.D. Port, co-P.I.) 07/22- 06/23

\$121,779 (total costs)

Title: Predoctoral training program in pharmacology INCLUDE Supplement

Supported 3 additional pre-doctoral trainees per year

FINANCIAL SUPPORT, MINOR GRANTS AND TRAINEE SUPPORT

University of Colorado

Mentor

UROP award to Neil Harris

\$750.00 for summer research project (1995)

Project Title: Regulation of β 1-AR mRNA

American Heart Association

Recipient, New Investigator Award (1996)

\$750 for travel to AHA Scientific Conference of the Molecular Biology of the Normal, Hypertrophied, and Failing Heart

University of Colorado

Mentor

Howard Hughes SURF award to Neil Harris

\$2000 for summer research project (1996)

Project Title: Translational effects on destabilization of human β 1-AR mRNA

Merck, Inc.

Recipient

Educational Grant to Department of Pharmacology

\$1000 (1997)

Astra-Merck, Inc.

Recipient

Educational Grant to Division of Cardiology

\$1000 (1997)

PhRMA Foundation

Mentor

Advanced Predoctoral Fellowship

Awarded to Burns C. Blaxall (graduate student, Dept. of Pharmacology)

\$25,000 for two years (4/97 to 3/99)

AstraZeneca, Inc.

Recipient

Educational Grant to Department of Pharmacology

9/25/25

\$5000 (1999)
AHA

Co-Mentor with Dr. Neel Mukherjee
Predoctoral Fellowship
Awarded to Kimberly Wellman (graduate student, Program in Molecular Biology)
\$62,032 over two years (1/2020 to 12/2021)

PATENTS

- 1998 U.S. Patent # 5,733,728. JD Port and G Brewer, “Detecting and treating heart failure”.
- 2001 U.S. Patent # 6,218,597 B1. JD Port and MR Bristow, “Transgenic Model and Treatment for Heart Disease”.
- 2001 U.S. Patent #6,203,776 B1. MR Bristow and JD Port, “Method for Identifying Adrenergic Receptor Antagonists Having Good Tolerability”.
- 2002 US Patent #6,436,636 B1. JD Port and G. Brewer. “Methods for identifying pharmacologicals for the treatment of heart failure”.
- 2007 U.S. Provisional Patent Application #xx “miRNAs as diagnostic and therapeutic targets in heart failure”. Withdrawn.
- 2009 U.S. Provisional Patent Application #WO2011079273A3 “Methods and compositions for the treatment of cardiovascular diseases and conditions”
- 2014 U.S. Application #US20100267804A1, WO2009012468A3, CA2693031A1. Differential Expression of microRNAs in nonfailing versus failing human hearts.
- 2017 European Patent Office Patent # EP2515899B1, MR Bristow and JD Port, Methods and compositions for cardiovascular diseases and conditions.
- 2015 U.S. Patent #8946284, MR Bristow and JD Port, “Methods and composition involving (S)-bucindolol”
- 2016 U.S. Patent #9446023, MR Bristow and JD Port, “Methods and composition involving (S)-bucindolol”
- 2017 U.S. Patent #9763916, 2018 U.S. Patent # 11452712. MR Bristow and JD Port, “Methods and composition involving (S)-bucindolol”
- 2018 U.S. Patent # 11452712. MR Bristow and JD Port, “Methods and composition involving (S)-bucindolol”

TEACHING

University of Utah Health Sciences Center:

Pharm 572. Cardiac glycosides and other positive inotropic agents in congestive heart failure. (lecture to third year pharmacy students) 1988 and 1989
Pharm 604. Cardiac glycosides and other drugs for congestive heart failure. (lecture to second year medical students) 1988 and 1989

University of Colorado Health Sciences Center:

Pharm 6000. Medical Pharmacology. (Lecture to second year medical students)
Cardiac glycosides and other drugs for congestive heart failure (2 hrs/year), 1993, 94, 95, 96, 97, 98, 99, 00, 01, 02, 03, 04, 05, 06

Pharm 6000 (continued) Treatment of angina (2 hrs/year), 1995, 96, 97, 98, 99, 00, 01, 02, 03, 04, 05, 06

Course reviewer/monitor for other lectures on cardiovascular topics, 1996, 97, 98, 99, 00, 01

Pharm 7620. Research topics. (lecture to first year pharmacology graduate students) 1992, 96, 97

Pharm 7620 Principles of Pharmacology (Graduate Pharmacology)

Cardiovascular Pharmacology, section organizer lecture to first year graduate students on G-protein coupled receptor signaling and on cardiac-related topics, receptor theory, personalized medicine, process of FDA drug approval. 6-12 lecture hours/year, every year from 1999-2024, 2025-, reduced lectures

Integrated Curriculum, First Year Medical Students

Treatment of Congestive Heart Failure, 2-3 hrs/year. 2006, 07, 08, 09, 10, 11, 12, 13, 14

Treatment of Angina, 1 hr/year. 2006, 07, 08, 09, 10, 11, 12

Integrated Clinicians Course 8005

Personalized Medicine, Pharmacogenomics. 2010

IDPT 7646 Tissue Biology and Disease Mechanisms

Lecture to graduate students on heart failure related topics. 2006

Pharm 7600 Frontiers in Pharmacology. Course Director and lecturer 1998. Literature-based directed reading/lecture course covering contemporary topics in pharmacology. 1999, 00, 01

Basic Science 6600 Dental Pharmacology. Course reviewer/monitor for lectures on cardiovascular topics, 1994, 95, 96, 97, 98, 99, 00

Pharm 7617 Molecular Pharmacology.

lecture to second year pharmacology grad students 1994, 95, 96, 97, 98

Path 6000 Alternative Pathology (lecture to MSTP and graduate students on the molecular basis of heart failure), 1994, 95, 96, 97, 98, 99, 00

Pharm 7605 Ethics in Research. Course Co-Director, 1999; small group discussion leader, 1999 00, 01, 2017, 2020, 2021, 2022, 2023 (7 to 8 discussion groups/yr)

*Pharm 7613. Journal Club. **Course Director***. Oversee and lead discussions in student driven Journal Club. Registration required for all 2nd and 3rd year pharmacology training program students. All other training program students are encouraged to attend. 2015/16, 16/17, 17/18, 18/19, 19/20, 20/21, 21/22, 22/23, 23/24, 24/25, 25/26

SOM Molecules to Medicine – Small Group Session facilitator. 2018, 19, 20

SOM Scientific Methods – Small Group Sessions facilitator. 2019

MolBio/Pharm 7801. Rigor & Reproducibility. Course co-director, lecturer. 2017; lecturer 2018, 19, 20, 21, 22

Pharm 7615 Grant Proposals in Pharmacology, 2009, 2011-24: lectures on grant writing, comprehensive exam process

Division of Cardiology: (lecture to cardiology fellows on basic pharmacological principles) 1996

Division of Cardiology: Director: Post-Doctoral Fellow/Graduate Student Journal Club, meets monthly, year-round. 2023-24

PEER REVIEW

Journals

Ad Hoc reviewer, Aging
Ad Hoc reviewer, Ageing Reviews
Ad Hoc reviewer, American Journal of Cardiology
Ad Hoc reviewer, American Journal of Physiology (various)
Ad Hoc reviewer, Anatomical Record
Ad Hoc reviewer, Atherosclerosis
Ad Hoc reviewer, Biochemical Genetics
Ad Hoc reviewer, Biochemical Pharmacology
Ad Hoc reviewer, Biochimica et Biophysica Acta
Ad Hoc reviewer, British Journal of Pharmacology
Ad Hoc reviewer, Cardiology
Ad Hoc reviewer, Cardiovascular Research
Ad Hoc reviewer, Circulation
Ad Hoc reviewer, Circulation Research
Ad Hoc reviewer, Circulation: Cardiovascular Genetics
Ad Hoc reviewer, Circulation: Heart Failure
Ad Hoc reviewer, Development
Ad Hoc reviewer, European Journal of Pharmacology
Ad Hoc reviewer, Experimental Cell Research
Ad Hoc reviewer, FASEB J
Ad Hoc reviewer, Heart
Ad Hoc reviewer, Heart and Vessels
Ad Hoc reviewer, Hypertension
Ad Hoc reviewer, Journal of the American College of Cardiology (JACC)
Ad Hoc reviewer, JACC: Heart Failure

Editorial Consultant, JACC: Basic to Translational Science

Ad Hoc reviewer, Journal of the American Medical Association (JAMA)
Ad Hoc reviewer, Journal of Applied Physiology
Ad Hoc reviewer, Journal of Biological Chemistry
Ad Hoc reviewer, Journal of Cardiovascular Pharmacology
Ad Hoc reviewer, Journal of Cardiac Failure
Ad Hoc reviewer, Journal of Clinical Investigation
Ad Hoc reviewer, Journal of Molecular Biology
Ad Hoc reviewer, Journal of Molecular and Cellular Cardiology
Ad Hoc reviewer, Journal of Molecular Medicine
Ad Hoc reviewer, Journal of Pharmacology and Experimental Therapeutics
Ad Hoc reviewer, Life Science
Ad Hoc reviewer, Life Science Alliance (EMBO press, Rockefeller Univ Press, CSHL Press)
Ad Hoc reviewer, Methods
Ad Hoc reviewer, Molecular and Cellular Biochemistry
Ad Hoc reviewer, Molecular and Cellular Biology
Ad Hoc reviewer, Molecular Pharmacology

Ad Hoc reviewer, Molecular Phylogenetics and Evolution
 Ad Hoc reviewer, Nucleic Acids Research
 Ad Hoc reviewer, Physiological Genomics
 Ad Hoc reviewer, Proc. Natl. Acad. Sci. U.S.A. (PNAS)
Guest Editor, Proc. Natl. Acad. Sci. U.S.A.
 Ad Hoc reviewer, RNA Biology
 Ad Hoc reviewer, Vascular Biology
 Ad Hoc reviewer, Science
 Ad Hoc reviewer, WIREs, RNA

Grant Review

Institutional

1996	University of Colorado, Health Sciences Center/School of Engineering Biomedical seed grant review committee
2014-15	CCTSI, K to R internal grant review
2017	Gift of Life and Breath, internal grant review
2018	CCTSI, CMH Pilot grant review
2019, 22	CCTSI, PreK grant review
2020, 21	CCTSI, Co-Pilot internal grant review
2020-23	SOM Scholar's Year
2021	AMC Pew Scholar's Internal Selection Committee
2022-25	PIKE Prep Selection Committee (Preparation in Interdisciplinary Knowledge to Excel
2022	CU Boulder/AMC AB Nexus Research Collaboration grant review
2023	CCTSI, K to R internal grant review
2024	CCTSI, K to R internal grant review (two rounds)
2025	CCTSI, PreK grant review
2025	CCTSI, Translational Methods Pilot Grant Program

International/National/Regional

1994	Member, American Heart Association, Western Consortium Peer Review Committee
1995,96,97	Member, American Heart Association, Affiliate Study Group G (Molecular Signaling) Committee
1998	Co-Chair , American Heart Association, Colorado/Wyoming Affiliate Peer Review Committee
1999, 2000	Chair , American Heart Association, Great America Affiliate Molecular Signaling (5E) Peer Review Committee
2001	Member, American Heart Association, Great America Affiliate Molecular Signaling (5E) Peer Review Committee
2002-03	Co-Chair , American Heart Association, Molecular Signaling II National Study Section
2002-03	Member (temporary), Pharmacology Study Section, NIH
2003-04	NIH, NHLBI, Program Project Grant reviewer (3 occasions)
2003	Member, Pharmacology Study Section, NIH
2004-07	Member, Vascular Cell and Molecular Biology Study Section, NIH
2007	Member (ad hoc), Training Grant review Study Section, NIH
2009	Member (ad hoc), Molecular Genetics "B" Study Section, NIH
2009	NIH, NHLBI, Program Project Grant reviewer

2010	Ad hoc reviewer, Netherlands Organization for Scientific Research
2011	Member (ad hoc), Molecular Genetics “B” Study Section, NIH
2012	International peer review, Health Research Board, Ireland
2012	International peer review, Agence Nationale de la Recherche, France
2013	Ad hoc reviewer, National Science Foundation (NSF)
2014-15	Ad hoc reviewer, Italian Ministry of Education, University and Research (MIUR)
2015	NIH, NHLBI, Program Project Grant reviewer
2015	Member (ad hoc), TWD-B Study Section, NIH
2015	Member, TWD-B T32 site visit review team
2019	Member, AHA Fellowships Basic Cell, Genetics and Epigenetics
2020/21	Member, AHA Basics Science GE Fellowships Peer Review
2021/22	Member, AHA Basics Sciences BCGE1 Fellowship Peer Review
2021/22	Member, NSF GRFP Biochemistry, Biophysics & Structural Biology Review
2022	Member, AHA Fellowship Basic Sciences 2 Peer Review
2022-23	Member, NSF GRFP Molecular and Systems Biology Review
2023	Member, AHA Fellowship Basic Sciences 2 Peer Review
2024	Member, NSF GRFP Molecular and Systems Biology Review

PROFESSIONAL MEMBERSHIPS

American Association for the Advancement of Science (inactive)
American Society for Microbiology (inactive)
American Society of Cell Biology (inactive)
American Heart Association, Professional Member, Basic Science Council
American Society of Biochemistry and Molecular Biology (inactive)
American Society of Pharmacology and Experimental Therapeutics, Division of Molecular Pharmacology (Member, Program Committee 1998-2006, inactive)
Heart Failure Society of America (Member, Program Committee 2000-2002) (inactive)
RNA Society

MENTORING & TRAINING

1991-97	Kelli Mitchusson, B.S.	PRA, now a practicing ER physician
1999	Amy Pellett, B.S.	PRA, lost to follow up
1993-01	Steven Wu, B.S.	PRA, now Ph.D. Assistant Professor, U MN
	Rasheeda Tanveer, B.S.	PRA, biotech in CA
1993-94	John Sherman, B.S.	summer student (M.D., currently practicing cardiologist)
1994-96	Aldo Pende, M.D.,	postdoctoral fellow (currently Professor at the University of Genoa, IT)
1994-96	Neil Harris	summer student (completed M.D. training)
1994-99	Burns Blaxall, Ph.D.	graduate student, Dept. of Pharmacology (Professor at University of Cincinnati)
1995-97	John Bisognano, M.D., Ph.D.	Bugher Post-doctoral Fellow, Cardiology (faculty, University of Rochester)
1998-99	Amornrate Sastravaha, DVM	research position in Thailand
1999-02	Violetta Headley, M.S.	PRA, Sr, Staff Scientist Illumina
2001	Scott Greene, B.S.	summer student, NCI research fellowship, Currently practicing MD (ENT)
2001	Pippa Cosper	summer student, NCI research fellowship, MD/PhD, Radiation Oncologist, UW Madison

2001	Carrie Eckert, B.S.	graduate student, Biomedical Sciences Program, currently Ph.D. Staff Scientist, NREL, CU Boulder
2001	Laura Zerbe, Ph.D.	co-mentor, post-doctoral fellowship
2002-04	Kathy Gleason, Ph.D.	postdoctoral fellow
2004	Brad Engel	summer student
2004	Leslie Adams	summer student, currently Nurse Practitioner
2005	Avery Berg	summer student (commissioned officer, Navy)
2005-12	Pamela David Gerecht, Ph.D.	postdoctoral fellow
2007	Molly Ann Taylor	graduate student, Biomedical Sciences Program
2007	Nicole Vitesse	summer student, NCI research fellowship
2007	Kelsey Flint, M.D.	medical student, research mentor program (currently, faculty in cardiology, AMC)
2008	Mary Zeng	summer student, NCI research fellowship
2014	Rachel Fickes	mentor, Pharmacology program, Major Seminar
2016	Jessica Hsu	mentor, Pharmacology program, Major Seminar
2019-	Kimberly Wellman	co-mentor for AHA predoctoral grant
2024	Lorena Alamillo	co-mentor for NIH F31 application

THESIS & COMPREHENSIVE EXAM COMMITTEES

1993-95	Ron Klein	thesis committee; chair, thesis defense committee
1996	Danny T. Muskardin	thesis committee; chair, thesis defense committee
1994-97	Mark Wade	comprehensive exam and chair thesis committee
1996	Sue Cibulsky	chair, comprehensive exam committee
1996	Michael Inman	comprehensive exam, thesis committee (Biochem)
1997	Elizabeth Gonzalez	comprehensive exam committee
1998/9	Eric Bush	thesis committee (Cell Structural Biology)
1999/00	Kalev Freeman	thesis committee (MCDB, UC Boulder, MSTP)
1999/01	Korinne (Meyer) Jew	thesis committee (Kinesiology, UC Boulder)
2001	Jason Prescott	comp exam, thesis committee (Mol Biol)
2003	Steven Rosinski	thesis committee (Pharmacology, MSTP)
2005/09	Todd Gangelhoff	comp exam, thesis committee (Mol Biol)
2006/10	Douglas Donham	comp exam, thesis committee (Pharmacology)
2007/09	Kelli Kline	comp exam, thesis committee (Pharmacology)
2009	Molly Ann Taylor	comp exam (Pharmacology)
2009-12	Patrick Hutchins	comp exam, chair thesis committee (Pharmacology)
2010-13	Sarah (Moore) Rogstad	chair, comp exam, chair thesis committee (Pharm)
2010	Allison Ostricker	chair, comp exam (Pharmacology)
2011	Wallace Liu	comp exam committee (Pharmacology)
2011	Christina Wysoczynski	chair, comp exam (Pharmacology)
2011-12	James Whitehurst	thesis committee (Pharmacology, MSTP)
2012	Sarah Williams	chair, comp exam, thesis committee (M.S., Pharm)
2012-15	Weston Blakeslee	chair, comp exam, thesis committee (Pharm)
2013-16	Jovylyn Gatchalian	chair, comps exam, thesis committee (Pharm)
2013-17	Jessica Spiltoir	chair, comps exam, thesis committee (Pharm)
2014	Rachel Fickes	chair, comps exam (Pharm)
2016-20	Andrew Riching	chair, comps exam, thesis committee (Pharm)
2017-22	Philip Tatman	comps committee (Pharm, MSTP)
2019-21	Wells LaRiviere	comps and thesis committee (Pharm, MSTP)
2019-22	Philip Tatman	thesis committee (Pharm, MSTP)
2020-21	Robert Jones	chair, thesis committee (Pharm, MSTP)
2020-25	Kathryn Walters	thesis committee (Mol Biol)
2020-23	Jacqueline Turner	chair, thesis committee (Pharm, MSTP)

2022-23	Austin Jolly	thesis committee (Pharm, MSTP)
2024-	Ralf Dagdad	chair, comps exam, thesis committee (Pharm)
2024-	Jiajun Li	thesis committee (Pharm)

COMMITTEES

University of Colorado System

2012-14	UPAC (University Accreditation) Committee
2012-16	Member, CU Faculty Council/Faculty Senate Executive Committee
2013-15	President's Task Force on Efficiency (PTFE)
2016-	Intercampus Tuition Benefit Task Force, Advisory Committee
2017-18	Faculty Council, Personnel & Benefits Committee
2019-21	Faculty Council, Budget Committee
2021	Search Committee, VP, Chief Technology Transformation Officer (on hold)
2022	Search Committee, VP and CFO, Office of the President

University of Colorado Health Sciences Center

1997-00	Judge, Annual Graduate Student Research Forum
1997	Recruitment and Admissions Committee, Consolidated Basic Sciences Graduate Program
1997-	Steering Committee, Consolidated Basic Sciences Graduate Program
1998-	UCHSC Graduate Council
1998-	SOM Graduate School Executive Committee
1998-	SOM Graduate School Executive Committee, Bylaws Subcommittee
2000	UCHSC Graduate School, Graduate School Rules Subcommittee
2001	UCHSC Graduate School Financial Resources Committee
2001-	UCHSC Fiscal Planning Committee
2003-12	Steering Committee, Medical Scientist Training Program (MSTP)
2003-12, 17-	UCHSC Faculty Assembly, member, representative Graduate School
2006-7	Chancellor's Committee on restructuring of UCDHSC graduate schools
2007	Core Course curriculum oversight committee
2008	Chancellor's Committee on restructuring of UCD Faculty Assemblies
2009-	UC Denver, Consolidated Graduate School Executive Committee
2009	RaCAS Committee
2009-10	Search Committee, Dean of the combined CU Denver Graduate Schools
2012-16	Chair, UC Denver AMC Faculty Assembly
2012	Strategic Vision: Research Task Force: Education, Training and Career Development Subcommittee
2013	Dean's Committee on Reorganization of the AMC Campus Basic Science Graduate Programs
2013-16	MD/PhD (MSTP) Admissions Committee (designated interviewer for Medical School)
2014	Academic Program Reviewer, Computational Biosciences Ph.D. Program
2014	Search Committee, Deputy Chief of Police, CU Denver, AMC Campus
2015	Academic Program Reviewer, Molecular Biology Ph.D. Program
2015	Search Committee, Director of TTO
2015	Search Committee, SV Chancellor for Administration & Finance
2016-	Director of Education, Consortium for Fibrosis Research and Translation (CFReT)
2016-21	Chair, MSTP Admissions Committee (5 years)
2016-21	MSTP Executive Committee

2016-22	Review Committee, SOM Scholar's Year Program
2017	Graduate School Biomedical Sciences Core Course Review Committee
2018-	SOM, Longitudinal Basic Sciences Team for Curriculum Reform Implementation
2018-	Liaison, AMC Innovations Program (Technology Transfer)
2019	SOM, PhD Program Taskforce
2019	Poster Judge, Research Day. University of Colorado Post-Doctoral Association
2019-23	MSTP Admissions Committee, Triage Review Subcommittee
2021-24	MSTP applicant interviewer
2020-22	SOM, Faculty Promotions and Tenure (P&T) Committee
2022-24	Co-Chair, SOM, Faculty Promotions and Tenure (P&T) Committee
2020-	Internal Advisory Board for Genetics of Disease, Development and Regeneration (GDDR) T32 Training Grant
2021-	Chancellor's Education Working Group for Strategic Priorities at CU/AMC
2021-	Grant Tracking Solutions Project Team (charter: to find SOM based replacement for GAIA, T32 training grant tables)
2020-	Internal Advisory Board for MSTP T32 Training Grant
2022	MSTP Annual Retreat, Poster Judge
2022	AMC Campus Faculty Graduate Council
2023	SOM Mentored Scholarly Activity, Poster Judge
2024	External Advisor, Molecular Biology T32 Training Program
2024-25	MSTP student F30/F31 mock study section
2024	Graduate School T32 Retreat Organizing Committee and Panel Member
2024	SOM Office of Research Education Faculty Council
2024-	MSTP Admissions Subcommittee

Department of Pharmacology/Pharmacology Training Program

1997-2022	Chair, Graduate Training Committee Director, Graduate Training Program, co-PI T32 Training Grant Chair (intermittently), Admissions Committee
1993-97	Graduate Training Committee
1994-97	Chair , Seminar Committee
1994	Committee: Role of Joint Appointments in the Department of Pharmacology
2001-	Graduate Student Recruitment/Admissions Committee (currently chair)
2001-	Curriculum Committee
2002	Department of Pharmacology Self-Study Committee
2010	Educational Retreat Organizing Committee
2011	Co-Director, ASPET, Summer Undergraduate Research Program
2012-14	ASPET, Summer Undergraduate Research Program, Admissions Committee
2018-	Chair, Pharmacology Department Graduate Student and Post-Doc Research Award Committee
2022-	Member, Graduate Training Committee

Department of Medicine/Division of Cardiology

1993-95	Role of Ph.D.'s in the Department of Medicine
1995	Research Directives Committee
1995-97	Core Curriculum Committee
1995-96	Chair , Seminar Committee
2004-06	Division of Cardiology, Executive Committee

2007-22 **Chair**, Divisional Research Seminar Committee
2009- Division of Cardiology Education Committee
2013, 16 Post Tenure Review Committee
2013-18 Roger Bannister, Ph.D., Junior Faculty Mentoring Committee
2014-18 Kunhua Song, Ph.D., Junior Faculty Mentoring Committee
2017-22 DOM Committee to Advance Gender Equity
2023-25 Midcourse Review Committee
2023-25 Director, Division of Cardiology Grant Rants/Chalk Talks
2023-24 Director, Division of Cardiology Post-Doc/Graduate Student Journal Club
2024-25 DOM, Associate to Full Professor P&T Committee

External

1997 Member, American Heart Association, Colorado/Wyoming Affiliate Research Committee
1998-01 Member (at large), Program Committee, American Society for Pharmacology and Experimental Therapeutics
1999-00 Member (ad hoc), Program Committee, Heart Failure Society of America
2000-02 Member, Program Committee, Heart Failure Society of America
2001-04 FASEB Summer Research Conferences Advisory Committee, ASPET representative
2001-13 Member (at large), ASPET, Division of Molecular Pharmacology, Executive Committee
2001-02 Research Committee, Desert Mountain Affiliate of the American Heart Association
2001-06 Representative to Program Committee, Division of Molecular Pharmacology, American Society of Pharmacology and Experimental Therapeutics
2003 Member, AHA Committee on implementation of grant review triage process
2003-05 Chair, Research Committee, Pacific Mountain Affiliate of the AHA
2003-05 Member, Board of Directors, Pacific Mountain Affiliate of the AHA
2003-05 Co-Chair, National AHA Peer Review Steering Committee
2005-07 Member, Strategic Planning Committee, Pacific Mountain Affiliate of the AHA
2005-07 Chair, National AHA Peer Review Steering Committee
2006-07 President Elect, Board of Directors, Pacific Mountain Affiliate of the AHA
2007-08 President, Board of Directors, Pacific Mountain Affiliate of the AHA
2008-09 Past President, Board of Directors, Pacific Mountain Affiliate of the AHA
2009 President Elect, Board of Directors, Denver Metro Board of the AHA
2009/10 President Elect, ASPET, Division of Molecular Pharmacology
2010/11 President, ASPET, Division of Molecular Pharmacology
2011/12 Past President, ASPET, Division of Molecular Pharmacology
2010/12 President, Board of Directors, Denver Metro Board of the AHA
2012/13 Past President, Board of Directors, Denver Metro Board of the AHA
2010 AHA Joint Operating Committee for merger of Pacific Mountain and South-Central Affiliates
2011/12 Member, Board of Directors, SouthWest Affiliate of the AHA
2011/12 Board Representative, Research Committee, SouthWest Affiliate of the AHA
2012/13 ASPET, Council of Division Chairs Representative
2013/15 Board of Directors, Denver Metro Board of the AHA
2015- Member Emeritus, Denver Metro Board of the AHA

OTHER SERVICE

- 1998 Session Moderator, Human Heart Failure: Molecular Mechanisms, AHA National Meeting
- 1998 Session Moderator, Biochemical Abnormalities in Failing Human Heart, AHA National Meeting
- 1999 Program Organizer/Chair, Short Course on “Surfing the Genome”, ASPET/Experimental Biology 99
- 1999 Session Moderator, Altered Intracellular Signal Transduction in Hypertrophy and Failure, Heart Failure Society of America National Meeting
- 2000 Session Moderator, G-proteins and Kinase Cascade Signaling Pathways, Heart Failure Society of America National Meeting
- 2000 Session Moderator, Workshop on “Mining the (Genomic) Data Bases”, Heart Failure Society of America National Meeting
- 2000 Session Moderator, Polymorphisms in Patients with Heart Failure, AHA National Meeting
- 2001 Abstract Grader, Heart Failure Society of America National Meeting
- 2001 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2001 Session Moderator, Adrenergic Mechanisms in Heart Failure, Heart Failure Society of America National Meeting
- 2002 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2002 Session Moderator, Genomics and Genetics, Part II, Heart Failure Society of America National Meeting
- 2003 Symposium Organizer/Chair, Transgenic Mouse Models of Heart Failure and Heart Failure Therapeutics, ASPET/Experimental Biology 03
- 2003 Meeting Co-organizer, First International Meeting on AREs and AUBPs in Translational Control, Florence, Italy
- 2003 Session Moderator, Late Breaking Science, Heart Failure Society of America National Meeting
- 2004 Symposium Organizer/Chair, Polymorphisms in signaling cascades and effector molecules, ASPET/Experimental Biology 04
- 2005 Session Moderator, Biological and therapeutic application of RNAi, Heart Failure Society of America National Meeting
- 2007 Symposium Organizer/Chair/Speaker, Post-transcriptional regulation of gene expression, ASPET/Experimental Biology 07
- 2008 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2008 Meeting Organizer, Invited Speaker, RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, Asheville, NC, 2008
- 2009 Symposium Organizer/Chair/Speaker, microRNAs as biological effectors and pharmacological targets in the cardiovascular system, ASPET/Experimental Biology 09
- 2009 Symposium Chair, Emerging concepts for microRNA in the failing heart, Heart Failure Society of America National Meeting
- 2010 Symposium Program Committee, Invited Speaker, 4th RNA Stability Meeting. RNA turnover and translation: biological and pathological ramifications 2010. Montreal, Canada

- 2010 Session Moderator, Targets for Improving Cardiac Function in Heart Failure, AHA National Meeting
- 2015 Meeting Organizer, Session Chair, Invited Speaker, RNA Turnover 2015. Estes Park, CO
- 2015 Panel Member, Workshop on NIH Training Grants, National Directors of Graduate Studies in Pharmacology and Physiology, Cincinnati, OH
- 2018 RNA Society Meeting, University of California, Berkeley, poster judge; career mentor
- 2019 Organizing Committee, RNA Turnover 2019. Montreal, Quebec, Canada

BIBLIOGRAPHY

Ph.D. Dissertation:

Port JD. I. Lack of spare β -adrenergic receptors in human ventricular myocardium. II. Pharmacological characterization of chick and frog myocardial β -adrenergic receptors. 1989

Book Chapters:

1. Bristow MR, **Port JD**: Receptor Pharmacology of the Human Heart. in, Current Concepts in Cardiovascular Physiology. O.B. Garfein ed., Academic Press. pp. 73-132, 1990.
2. **Port JD**, Pende A, Valent S, Bristow MR. Adrenergic Receptors: Relevance to Myocardial Signal Transduction in Heart Failure. L. Dei Cas and C. V. Leier, eds. UTET Periodici Scientifici srl. pp 8-19, 1995
3. Abraham WT, **Port JD**, Bristow MR. Neurohormonal Receptors in the Failing Heart. In: Heart Failure. Poole-Wilson PA, Chatterjee K, Coats AJS, Colucci WS, Massie B. eds. New York, Churchill Livingstone pp 127-141, 1997
4. Blaxall BC, **Port JD**. Binding of adrenergic receptor mRNA to cellular proteins: use of UV cross-linking and other methods for identification and determination of size and affinity. In: Methods in Molecular Biology. Adrenergic Receptor Protocols. Curtis Machida, editor. Humana Press, Inc. vol. 136, pp. 453-465, 2000
5. Bristow MR, **Port JD**, Kelley R, Chapter 18. Drugs Used to Treat Heart Failure. In: Heart Disease. A Textbook of Cardiovascular Medicine. 6th Edition. Braunwald E, Zipes D, and Libby P. eds. W.B. Saunders Co., pp. 562-599, 2001
6. Bristow MR, **Port JD**, Kelley R, Pharmacologic Management of Congestive Heart Failure. In: Cardiovascular Therapeutics 2nd Edition: A Companion to Braunwald's Heart Disease. Antman, E.M., ed. W.B. Saunders Co., pp300-324, 2002
7. **Port JD**, Linseman J, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: Heart Failure: A Companion to Braunwald's Heart Disease. Mann, D.L., ed. W.B. Saunders Co., pp 145-158, 2004
8. Bristow MR, Linas S, and **Port JD**, Drugs in the Treatment of Heart Failure. In: Heart Disease. A Textbook of Cardiovascular Medicine. 7th Edition. Braunwald E, Zipes D, and Libby P. eds. Ch 23, pp 569-601, 2005
9. **Port JD**, and Bristow MR. Adrenergic Receptor Coupling and Uncoupling in Heart Failure In: Molecular Mechanisms for Cardiac Hypertrophy and Failure Richard A. Walsh, M.D., Editor, Ch 20 pp 323-340, 2005
10. **Port JD**, Sucharov C, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: Heart Failure: A Companion to Braunwald's Heart Disease 2nd Edition. Mann, D.L., ed. W.B. Saunders Co. Ch 10 pp 152-162, 2011
11. **Port JD**, Sucharov C, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: Heart Failure: A Companion to Braunwald's Heart Disease 3rd Edition. Mann, DL, and Felker GM, eds. Ch 6 pp 94-108, 2015 (awarded 1st Prize in Cardiology in 2016 by the British Medical Association Book Awards)

12. **Port JD**, Sucharov C, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: Heart Failure: A Companion to Braunwald's Heart Disease 4th Edition. Mann, DL, and Felker GM, eds., 2020
13. **Port JD**, Sucharov C, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: Heart Failure: A Companion to Braunwald's Heart Disease 5th Edition. Mann, DL, and Felker GM, eds., 2025 (in press)

Manuscripts (selected, from a total of 82)

1. Meuleman TR, Hill DC, **Port JD**, Stanley TH, Pace NL, Mohammad SF: Ketanserin prevents platelet aggregation and endotoxic-induced pulmonary vasoconstriction. Crit Care Med 11:606-611, 1983
2. Wong KC, **Port JD**, Steffens JG: Cardiovascular responses to asphyxial challenge in chronically hypokalemic dogs. Anesth Analg 62:991-994, 1983
3. Wong KC, Tseng CK, Puerto BA, Puerto AX, Liu WS, **Port JD**: Chronic hypokalemia on epinephrine induced dysrhythmias during halothane, enflurane, or methoxyflurane with nitrous oxide anesthesia in dogs. Anes Sinica 21:139-146, 1983
4. Clark NJ, **Port JD**, McJames SW, Stockham RJ, Stanley TH, Pace NL: Preservation of the ischemic canine myocardium: a comparison of hypothermia, lidoflazine, and ketanserin. J Cardiothor Anes 2(3):330-340, 1988
5. Bristow MR, Hershberger RE, **Port JD**, Minobe W, Rasmussen R: β_1 & β_2 adrenergic receptor mediated adenylyl cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharm. 35:295-303, 1989
6. Bristow MR, **Port JD**, Hershberger RE, Gilbert EM, Feldman AM: The β -adrenergic receptor-adenylyl cyclase complex as a target for therapeutic intervention in heart failure. Europ Heart J 10(Suppl B)45-54, 1989
7. Gilbert EM, **Port JD**, Hershberger RE, Bristow MR: Clinical significance of alterations in the β -adrenergic receptor-adenylyl cyclase complex in heart failure. Heart Failure 5:91-98, 1989
8. Bristow MR, **Port JD**, Sandoval AB, Rasmussen R, Ginsburg R, Feldman AM: Beta-adrenergic receptor pathways in the failing human heart. Heart Failure 5:77-90, 1989
9. Bristow MR, **Port JD**, Gilbert EM: The role of receptor regulation in the treatment of heart failure. Cardiovasc Drugs & Therapy 3:971-978, 1990
10. **Port JD**, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Bristow MR: Neurotransmitter depletion compromises the ability of indirect acting amines to provide inotropic support in the failing human heart. Circulation 81:929-938, 1990
11. Bristow MR, Hershberger RE, **Port JD**, Sandoval A, Rasmussen R, Cates AE, Feldman AM: β -adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82(S1):I12-I25, 1990
12. Bristow MR, Anderson FL, **Port JD**, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM: Differences in β -adrenergic neuroeffector mechanisms in ischemic vs. idiopathic dilated cardiomyopathy. Circulation 84:1024-1039, 1991
13. Hadcock JR, **Port JD**, Malbon CC: Cross-regulation between G-protein mediated pathways: activation of the inhibitory pathway of adenylyl cyclase increases the expression of β_2 -adrenergic receptors. J Biol Chem 266:11915-11922, 1991
14. Lee HR, Hershberger RE, **Port JD**, Rasmussen R, Renlund DG, O'Connell JB, Gilbert EM, Mealey PC, Volkman K, Menlove R, Bristow MR: Low-dose enoximone in subjects awaiting cardiac transplant: clinical results and effects on β -adrenergic receptors. J Thorac Cardiovasc Surg 102:246-258, 1991

15. Anderson FL, **Port JD**, Reid BB, Larrabee P, Hanson G, Bristow MR: Myocardial catecholamines and neuropeptide-Y depletion in the failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta adrenergic receptor down-regulation. *Circulation* 85:46-53,1992
16. Anderson FL, **Port JD**, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR: Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. *J Cardiovasc Pharm* 20:800-806, 1992
17. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, **Port JD** and Muller-Beckmann B: Receptor pharmacology of carvedilol in the human heart. *J Cardiovasc Pharmacol* 19(S1):S68-S80, 1992
18. Hadcock JR, **Port JD**, Gelman MS and Malbon CC: Cross-talk between tyrosine kinase and G-protein-linked receptors: phosphorylation of β_2 -adrenergic receptors in response to insulin. *J Biol Chem* 267:26017-26022, 1992
19. **Port JD**, Hadcock JR, and Malbon: Cross-regulation between G-protein-mediated pathways: acute activation of the inhibitory pathway of adenylylcyclase reduces β_2 -adrenergic receptor phosphorylation and increases β -adrenergic receptor responsiveness. *J Biol Chem* 267:8468-8472, 1992
20. **Port JD**, Huang L-Y, and Malbon CC: β -adrenergic agonists that down-regulate receptor mRNA up-regulate a 35,000-Mr proteins(s) that selectively binds to β -adrenergic receptor mRNAs. *J Biol Chem* 267:24103-24108, 1992
21. **Port JD**, Debellis C, Wiederin J, Peeters G, Barry WH, Bristow MR: Pharmacological characterization of cultured chick and frog myocardial β -adrenergic receptors. *J Pharmacol Exper Ther* 262:217-224, 1992
22. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, **Port JD**: Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. *The Clinical Investigator (Klinische-Wochenschrift)* 70(S1):S105-S113,1992
23. **Port JD**, and Malbon CC: Integration of transmembrane signaling: cross-talk among G-protein-linked receptors and other signal transduction pathways. *Trends Cardiovasc Med* 3:85-92, 1993
24. Farrukh HM, White M, **Port JD**, Handwerger DA, Larrabee P, Klein J, Roden R, Skerl L, Renlund DG, Feldman AM, and Bristow MR: Up-regulation of β_2 -adrenergic receptors in previously transplanted, denervated nonfailing human hearts. *JACC* 22:1902-1908, 1993
25. Bristow MR, Minobe WA, Reynolds MV, **Port JD**, Rasmussen R, Ray PE, and Feldman AM. Reduced β_1 -receptor mRNA abundance in the failing human heart. *J Clin Invest* 92:2737-2745, 1993
26. White M, Roden RL, Skerl L, Larrabee P, Wollmering MM, **Port JD**, Minobe W, Anderson FA, Feldman AF and Bristow MR: Age-related changes in the β -adrenergic neuroeffector systems in the human heart. *Circulation* 90:1225-1238, 1994
27. White M, Wiechmann RJ, Roden RL, Hagen MB, Wollmering MM, **Port JD**, Hammond E, Abraham WT, Wolfel EE, Lindenfeld JA, Fullerton D, Bristow MR. Cardiac β -adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: evidence for catecholamine-mediated myocardial damage. *Circulation* 92:2183-2189 1995
28. Yoshikawa T, **Port JD**, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J* 16(Suppl B):8-16, 1996
29. Pende A, Tremmel KD, DeMaria CT, Blaxall BC, Minobe W, Sherman JA, Bisognano J, Bristow MR, Brewer G, **Port JD**. Regulation of the mRNA binding protein, p37AUF1, by

- activation of the β -adrenergic receptor signal transduction pathway. *J Biol Chem* 271:8493-8501, 1996
30. Asano K, Dutcher DL, **Port JD**, Minobe WA, Tremmel KD, Roden RL, Bohlmeier TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman, LS, Perryman MB, and Bristow MR. Selective down-regulation of the angiotensin II AT1 receptor subtype in failing human ventricle. *Circulation* 95:1193-1200, 1997
 31. Bristow MR and **Port JD**. β -adrenergic blockade in chronic heart failure. *Scand Cardiovasc J* (S47):45-55, 1998
 32. Mitchusson KD, Blaxall BC, Pende A, and **Port JD**. Agonist-mediated destabilization of human β 1-adrenergic receptor mRNA; role of the 3' untranslated region. *Biochem Biophys Res Comm* 252:357-362, 1998
 33. Pende A, Giacche M, Castigliola L, Contini L, Passerone, G, Patrone M, **Port JD**, and Lotti G. Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. *Biochem Biophys Res Comm* 266:609-614, 1999
 34. Blaxall BC, Pellet A, Wu SC, Pende A, and **Port JD**. Purification and characterization of β -adrenergic receptor mRNA binding proteins. *J Biol Chem* 274:4290-4297, 2000
 35. Bisognano JD, Weinberger, HD, Bohlmeier TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, and **JD Port**. Myocardial-directed overexpression of the human β 1-adrenergic receptor in transgenic mice. *J Mol Cell Cardiol* 32:817-830, 2000
 36. Gilbert EM, and **Port JD**. Deactivation of the sympathetic nervous system in patients with CHF: should we aim for full or partial beta-adrenergic blockade? *Current Cardiology Reports* 2:225-232, 2000
 37. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeier TJ, Brewer G, Malkinson AM, and **Port JD**. Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA-binding protein (AUF1) and Hu antigen R (HuR) in neoplastic lung tissue. *Molecular Carcinogenesis* 28:76-83, 2000
 38. Asano K, Zisman, LS, Yoshikawa T, Headley V, Bristow MR and **Port JD**. Bucindolol, a nonselective β 1- and β 2-adrenergic antagonist, decreases β -adrenergic receptor density in embryonic chick ventricular myocyte membranes. *J Cardiovasc Pharm* 37:678-691, 2001
 39. **Port JD**, and Bristow MR. Altered β -adrenergic receptor signaling in chronic heart failure. *J Mol Cell Cardiol* 33:887-905, 2001
 40. **Port JD**, and Bristow MR. Perspective: β -adrenergic receptors, transgenic mice, and pharmacological model systems. *Mol Pharmacol* 60:629-631, 2001
 41. Blaxall B, Pende A, Wu, S.C., and **Port JD**. Correlation between intrinsic mRNA stability and affinity of the mRNA binding proteins, AUF1(hnRNP D) and HuR, for A+U-rich mRNAs. *Mol Cell Biochem* 232:1-11, 2002
 42. Communal C, Colucci WS, Remondino A, Sawyer DB, **Port JD**, Wichman SE, Bristow MR, and Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. *J Cardiac Failure* 8:86-92, 2002
 43. Asano K, Bohlmeier TJ, Westcott JY, Zisman LS, Kinugawa K, Good M, Minobe WA, Roden RL, Wolfel EE, Lindenfeld J, **Port JD**, Perryman MB, Cleveland J, Lowes B, and Bristow MR. Altered expression of endothelial receptors in failing human left ventricles. *JMCC* 34:833-846, 2002
 44. Pino I, Zerbe LK, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, **Port JD**, Montuenga LM, and Malkinson AM. The relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth; implications of pre-mRNA processing. *Mol Carcinogenesis* 41:187-196, 2004

45. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, **Port, JD**, Lavori PW, and Bristow MR. A polymorphism within a conserved β 1-adrenergic receptor motif alters cardiac function and β -blocker response in human heart failure. *PNAS* 103:11288-11293, 2006
46. David P, Tanveer R, and **Port JD**. FRET-detectable interactions between the ARE binding proteins, HuR and p37AUF1. *RNA* 13:1453-1468, 2007
47. Vest RS, Davies KD, O'Leary H, **Port JD**, and Bayer KU. Dual mechanism of a natural CaMKII inhibitor blocks substrate but not T286 auto-phosphorylation. *Mol Biol Cell* 18:5024-5033, 2007
48. Pende A, Contini L, Sallo R, Passalacqua M, **Port JD**, and Lotti G. Characterization of RNA-binding proteins involved in the modulation of hAT1 receptor mRNA stability. *Cell Biochemistry and Function* 26:493-501, 2008
49. Sucharov K, Bristow MR, and **Port JD**. Regulation of miRNA expression in the failing human heart: functional correlates. *JMCC* 45:185-192, 2008
50. Bristow MR, Murphy GA, Small KM, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, **Port JD**, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, and Liggett SB. An alpha2c-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response to the beta-blocker bucindolol in chronic heart failure. *Circulation: Heart Failure* 3:21-28, 2010
51. **Port JD** and Sucharov K. miRNA regulation in cardiovascular disease. *J Cardiovasc Pharm* 56:444-453, 2010
52. Gerecht PD, Taylor MA and **Port JD**. Intracellular localization of mRNA binding proteins as detected by FRET. *BMC Cell Biology* 11:69, 2010 (doi:10.1186/1471-2121-11-69)
53. **Port, JD**, Walker L, Polk J, Nunley K, Buttrick P, Sucharov CC. Temporal expression of miRNAs and mRNAs in a mouse model of myocardial infarction. *Physiological Genomics* 43:1087-1095, 2011
54. **Port, JD** and Bristow MR. Editorial: Aptamer therapy for heart failure? *Circ Res* 109:982-983, 2011
55. Dockstader K, Nunley K, Medaway A, Nelson P, **Port JD**, Liggett SB, Bristow MR, and Sucharov CC. Temporal Analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the beta1-adrenergic receptor. *Physiological Genomics* 43:1294-1306, 2011
56. **Port, JD**. Beta-receptor signaling complexities and therapeutic relevance to heart failure. *Current Signal Transduction Therapy* 7:120-131, 2012
57. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh, R, Nelson P, Medway A, Davis G, Robertson AD, **Port JD**, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, and Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2c adrenergic receptor polymorphisms. *PLoSOne* 7(10):1-9, e44324, 2012
58. Aleong RG, Sauer WH, Davis, D, Murphy GA, **Port JD**, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, and Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta-1 Arg/Gly adrenergic receptor polymorphism. *JACC Heart Failure* 1:338-344, 2013
59. Werahera PN, Jaison EA, Crawford ED, La Rosa FG, Lucia S, van Bokhoven A, Sullivan HT, **Port JD**, Maroni PD, and Daily JW. Systematic diagnosis of prostate carcinoma using an optical biopsy needle adjunct with fluorescence spectroscopy. *IEEE EMBS* 2014 Aug; 2014:2165-8. doi: 10.1109/EMBC.2014.6944046.

60. Hinterberg MA, Kao DP, Bristow MR, Hunter LE, **Port JD**, and Gorg C. PEAX: Interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pacific Symp Biocomput 20:419-430, 2015
61. Avasarla S, Van Scoyk M, Rathinam MKK, Zerayesus S, Zhao X, Zhang W, Perande MR, Borgia JA, DeGregori J, **Port JD**, Winn RA, and Bikkavilli RA, PRMT1 is a novel regulator of epithelial-mesenchymal transition in non-small cell lung cancer. J Biol Chem 290:13479-13489, 2015
62. Lindenfeld J, Cleveland JC, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert M, Ambardekar AV, Minobe W, **Port JD**, and Bristow MR. Sex-related differences in age-associated down-regulation of human ventricular myocardial beta1-adrenergic receptors. J Heart Lung Transplant 35:352-361, 2016
63. Werahera PN, Jaison EA, Crawford ED, La Rosa FG, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, **Port JD**, Daily JW, and La Rosa FG. Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. IEEE EMBS, 2016
64. **Port, JD**, and Bristow MR. Editorial Comment: Fine tuning adenylyl cyclase as a (gene) therapy for heart failure. JACC: Basic to Translational Science, DOI:10.1016/j.jacbs.2016.10.005, 2016
65. Sucharov CC, Kao DP, **Port JD**, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, and Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight doi:10.1172/jci.insight.89169, 2017
66. Shah P, Bristow MR, and **Port JD**. MicroRNAs in heart failure, cardiac transplantation, and myocardial recovery: biomarkers with therapeutic potential. Current Heart Failure Reports DOI 10.1007/s11897-017-0362-8, 2017
67. **Port JD**. Potential for AT1-R biased-agonists in Pediatric Heart Failure. JACC: Basic to Translational Science, 2020 5(11):1070-1072, doi: 10.1016/j.jacbs.2020.09.008. eCollection 2020 Nov. PMID: 33296444 PMCID: [PMC7691276](https://pubmed.ncbi.nlm.nih.gov/PMC7691276/) DOI: [10.1016/j.jacbs.2020.09.008](https://doi.org/10.1016/j.jacbs.2020.09.008)
68. Robinson EL, and **Port JD**. State of the Art Review: Utilization and Potential of RNA-based Therapies in Cardiovascular Disease. JACC: Basic to Translational Science. 2022, 7(9):956-969 <https://doi.org/10.1016/j.jacbs.2022.02.003>
69. **Port, JD**. Editorial Comment: Dissecting Beta-adrenergic receptors: the sum of many parts. JACC: Basic to Translational Science, 2023 (in press)
70. Tatman PD, Kao DP, Chatfield KC, Carroll, IA, Wagner JA, Jonas ER, Sucharov CC, **Port JD**, Lowes BD, Minobe WA, Huebler SP, Karimbour-Fard A, Rodriguez, EM, Liggett SB, and Bristow MR. An extensive beta1-adrenergic receptor gene signaling network regulates molecular remodeling dilated cardiomyopathies. JCI Insight. 2023;**8(16)**:e169720. <https://doi.org/10.1172/jci.insight.169720>.

Manuscripts (submitted or in preparation):

1. Tanveer R, Greene S, and **Port JD**. Regulation of AUF1 mRNA binding by MAPK phosphorylation. (submitted, in revision)
2. Polk J, and **Port JD**. Interdependent regulation of HuR and miRNAs regulating beta-AR gene expression. (in preparation)

Abstracts (selected from a total of 133)

1. Webster LR, Stanley TH, **Port JD**, Johansen R: Comparison of intravenous nitroglycerin and sodium nitroprusside on hypoxic pulmonary vasoconstriction. Presented at the annual meeting of the American Society of Anesthesiologists, 1978 Abstracts, pg. 67

2. Webster LR, Stanley TH, Razzeca K, **Port JD**: Comparison of cardiopulmonary bypass with membrane and bubble oxygenators on leukocyte phagocytosis during halothane anesthesia. Presented at the annual meeting of the American Society of Anesthesiologists, 1978 Abstracts, pg. 95
3. **Port JD**, Stanley TH, Steffey EP: Narcotic inhalation anesthesia. *Anesthesiology* 57:A344, 1982
4. **Port JD**, Steffey EP, Stanley TH, Henrickson R: Carfentanil: the primate experience. Presented at the annual meeting of the American College of Veterinary Anesthesiologists, 1983 Abstracts, pg. 45
5. **Port JD**, Stanley TH, Steffey EP, Pace NL, Henrickson R, McJames SW: Intravenous carfentanil in the dog and rhesus monkey. *Anesthesiology*, 61:A378, 1984
6. Dzelzkalns R, Bailey PL, **Port JD**, Pace NL, Stanley TH, Kimball J: Potentiation of opioid anesthesia without additional respiratory depression. Presented at the annual meeting of the Southern Society of Anesthesiologists, 1985
7. **Port JD**, Sakashita C, Rollins DE: Immunoabsorption mediated extraction of fentanyl from biological specimens. *Fed Proc.* 46(3):400, 1987
8. **Port JD**, Bristow MR: Myocardial β_2 receptor subsensitivity in the failing heart. *JACC* 11(2):117A, 1988
9. **Port JD**, Bristow MR: Lack of spare β -adrenergic receptors in the human heart. *FASEB J* 2(4):A602, 1988
10. **Port JD**, DeBellis CC, Bristow MR: Pharmacologic characterization of cultured chick and frog myocardial β -adrenergic receptors. *Pharmacologist* A96, 1988
11. Hershberger RE, **Port JD**, Anderson FL: Somatostatin inhibits adenylate cyclase in human ventricular myocardium. *Circulation* 78(S2):560, 1988
12. **Port JD**, Hershberger RE, Gilbert EM, Bristow MR: β -adrenergic agonists in nonfailing, failing and transplanted human hearts *JACC* 13(2):143A, 1989
13. **Port JD**, DeBellis CC, Wiederin J, Peeters GA, Hershberger RE, Barry WH, Bristow MR: Long-term β -adrenergic receptor desensitization in cultured chick myocardial cells. *FASEB J* 3(4):A1044, 1989
14. **Port JD**, Larrabee P, Wiederin J, Durham D, Rasmussen R, Bristow MR: Differences in ventricular myocardial β -receptor expression in ischemic vs. idiopathic dilated cardiomyopathy. *Circulation* 80(S2):8, 1989
15. **Port JD**, Skerl L, O'Connell JB, Renlund D, Larrabee P, Bristow MR: Increased expression of β_2 -receptors in surgically denervated, previously transplanted human ventricular myocardium. *JACC* 15(2):84A, 1990
16. Wiechmann RJ, Eastburn T, Murray J, **Port JD**, O'Connell JB, Renlund DG, Hershberger RE, Bristow MR: Cardiac donor dysfunction: evidence for catecholamine-mediated myocardial injury. *JACC* 15(2):84A, 1990
17. Anderson FL, **Port JD**, Bristow MR, Hershberger RE, Kralios A, Hanson G: Neuropeptide Y in the failing human ventricle of patients with idiopathic dilated cardiomyopathy. *JACC* 15(2):30A, 1990
18. Wollmering MM, Wiechmann RJ, **Port JD**, Hershberger RE, Focaccio A, Bristow MR: Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. *JACC* 17(2):283A, 1991
19. Bristow MR, Durham C, Klien J, Rasmussen R, **Port JD**, Gesteland RR, Barry WH, Feldman AM: Down-regulation of β -adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. *Clin Research* 39:256A, 1991
20. White M, Wollmering M, Roden RL, **Port JD**, Minobe W, Skerl L, Handwerger DA, and Bristow MR: Decreased G protein functional activity, decreased agonist affinity and

- uncoupling of β -adrenergic receptors from mechanical response with aging in the human heart. *Circulation* 86(S1):I-766, 1991
21. Bristow MR, Handwerger DA, Klein J, and **Port JD**: Down-regulation of cardiac β_1 -adrenergic receptors by “atypical” β -blocking agents. *Circulation* 86(S1):I-646, 1992
 22. White M, Wollmering M, Roden R, **Port JD**, Minobe W, Skerl L, Handwerger H, and Bristow MR: Age-related decrease in β -adrenergic responsiveness is not expressed in previously transplanted, denervated human heart. *Can J Cardiol* 8(Suppl B):96B, 1992
 23. Bristow MR, Minobe W, **Port JD**, Ray PE, and Feldman AM: Decreased β_1 -adrenergic receptor mRNA levels correlate with decreased β_1 -receptor density in the failing human heart. *JACC* 21(2):100A, 1993
 24. White M, Wollmering M, Roden RL, **Port JD**, Minobe W, Skerl L, Handwerger DA, and Bristow MR: Decreased G protein functional activity, decreased agonist affinity and uncoupling of β -adrenergic receptors from mechanical response with aging in the human heart. *Can J Cardiol* 8(Suppl B):131B, 1993
 25. Bristow MR, Minobe WA, Reynolds MV, Roden RL, **Port JD**, and Feldman AM. Age-related decreases in β_1 -receptor mRNA abundance in human heart. *JACC* 23:17A, 1994
 26. Lindenfeld J, White M, Roden RA, **Port JD**, and Bristow MR: Gender-related differences in age-associated down-regulation of human ventricular myocardial β -adrenergic receptors. *Clinical Research* 42:333A, 1994
 27. Mitchusson K, Pende A, Minobe W, Blaxall B, Bristow MR, and **Port JD**. Up-regulation of AUF1, an mRNA binding protein, in failing human ventricular myocardium. Cold Spring Harbor Symposium on Translational Control, Abstracts: pg. 164, 1994
 28. Lowes BD, Chidiac P, Olsen S, **Port JD**, Bouvier M, Gilbert EM, and Bristow MR. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β adrenergic receptor blocking agents. *Circulation* 90(4):I-543, 1994
 29. Asano K, Minobe W, Mitchusson KD, Dutcher D, Roden R, **Port JD**, & Bristow MR. Selective down-regulation of angiotensinogen II AT1 receptors in failing human heart: relationship to β_1 -receptor down-regulation. *JACC* (Feb):291A, 1995
 30. **Port JD**, Mitchusson KD, Pende A, Minobe M, Brewer G, Bristow MR. Regulation of p37AUF1, an mRNA binding protein, in human ventricular myocardium. *FASEB J* 9(6):A1277, 1995
 31. Blaxall B, Mitchusson KD, Pende A, Brewer G, **Port JD**. β -adrenergic receptor mediated regulation of p37AUF1, an mRNA binding protein, in DDT1-MF2 cells. *FASEB J* 9(6):A1277, 1995
 32. Pickrell JW, Abraham WT, **Port JD**, Roden RL, Bristow MR, Hammond EH. Evidence for decreased adrenergic nerve density in the failing human heart. *Circulation* 92:I-191, 1995
 33. Mitchusson KD, Roden RL, Abraham WT, Bristow MR, **Port JD**. Regulation of the norepinephrine transporter by its endogenous ligand. *Circulation* 92:I-568, 1995
 34. Roden RL, Minobe W, Dutcher DL, Tremmel KD, **Port JD**, Bristow MR. Differential regulation of β_1 - and β_2 -adrenergic receptors and mRNA by nonselective β -agonist exposure in preparation of isolated human heart. *JACC* 27(Suppl A):288A, 1996
 35. Pende A, DeMaria CT, Sherman J, Tremmel KD, Brewer G, **Port JD**. Binding of p37AUF1, an mRNA destabilizing protein, to human β_1 -adrenergic receptor mRNA. *Keystone Symposia: Molecular Biology of the Cardiovascular System*, pg. 47, 1996
 36. Tremmel KD, Pende A, Bristow MR, **Port JD**. Regulation of human β_1 -adrenergic receptor mRNA stability by agonist exposure. *Keystone Symposia: Molecular Biology of the Cardiovascular System*, pg. 47, 1996

37. Tremmel KD, and **Port JD**. Regulation of human beta1-adrenergic receptor mRNA stability. American Heart Association Scientific Conference on the Molecular Biology of the Normal, Hypertrophied, and Failing Heart, abstract #60, 1996
38. Bristow MR, Abraham WT, Gilbert EM, Yoshikawa T, and **Port JD**. Relationships between carvedilol stereoisomer plasma concentrations and β -receptor occupancies in subjects with chronic heart failure in the MOCHA trial. *European Heart J* 17(Suppl):135, 1996
39. Tremmel KD, and **Port JD**. Regulation of beta1-adrenergic receptor mRNA stability: critical role of the 3' untranslated region. *Mol Biol Cell* 7:300a, 1996
40. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. *Mol Biol Cell* 7:300a, 1996
41. Lowes BD, Abraham WT, Dutcher DL, Roden RL, Crisman TS, Minobe W, **Port JD**, Larrabee P, Gilbert EM, and Bristow MR. Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled trial. *Circulation* 94:I-664, 1996
42. Tremmel KD, and **Port JD**. Regulation of beta1-adrenergic receptor mRNA stability: role of the 3' untranslated region. *Circulation* 94:I-288-9, 1996
43. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. *Circulation* 94:I-407, 1996
44. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential affinities of the mRNA binding protein, AUF1, for beta-adrenergic receptor mRNAs. *Cold Spring Harbor Symposium on Translational Control*. Abstracts, pg. 37, 1996
45. Tremmel KD and **Port JD**. Regulation of human beta1-adrenergic receptor mRNA stability: critical role of the 3'UTR. *Cold Spring Harbor Symposium on Translational Control*. Abstracts, pg. 271, 1996
46. Lowes BD, Minobe WA, Abraham WT, Roden RL, **Port JD**, Gilbert EM, Larrabee P, and Bristow MR. Downregulation of α - and upregulation of β -myosin heavy chain in intact, failing human ventricles. *JACC* 25(Suppl A):422A-423A, 1997
47. Bisognano JD, Pende A, Tremmel KD, Dutcher DL, Knudson OA, Bohlmeier TJ, Bristow MR, and **Port JD**. Preliminary characterization of a transgenic mouse overexpressing the human β 1-adrenergic receptor. *J Invest Med* 45:210A, 1997
48. Tremmel KD, Pende A, Blaxall B, and **Port JD**. The 3' untranslated region of the human beta1-adrenergic receptor is necessary but not sufficient for agonist-mediated destabilization. *Circulation* 96:I-52, 1997
49. Vickstrom KL, Weinberger HD, Hoover E, **Port JD**, Knudsen OA, Valdes-Cruz L, Bristow MR, and Leinwand LA. Hypertrophy- and dilation-associated genes in murine cardiomyopathy. *Circulation* 96:I-570, 1997
50. **Port JD**, Weinberger HD, Bisognano JD, Knudson OA, Bohlmeier TJ, Pende A, and Bristow MR. Echocardiographic and histopathological characterization of young and old transgenic mice overexpressing the human β 1-adrenergic receptor. *JACC* 31(Suppl A):177A, 1998
51. Wichman SE, Minobe WA, Roden RL, **Port JD**, Asano K, Bristow MR. Differential regulation of β 1- and β 2-adrenergic receptor proteins, and β 1-adrenergic receptor protein and mRNA expression in response to β -agonist exposure in isolated human heart preparations. *Circulation* 98(17):I-491, 1998
52. Blaxall BC, Keil KH, Bohlmeier TJ, Bristow MR, Brewer G, Malkinson AM, and **Port JD**. Association of the mRNA binding protein AUF1 with growth phenotype. *Cold Spring Harbor Symposium on Translational Control*, Abstracts: pg. 46, 1998
53. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeier TJ, Brewer G, Malkinson AM, and **Port JD**. Elevated expression of the mRNA binding protein AUF1 in mouse lung tumors. *Proc Am Assoc Cancer Res* 40:438, 1999

54. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeier TJ, Brewer G, Malkinson AM, and **Port JD**. Expression of the mRNA binding protein AUF1 correlates with growth. *FASEB J* 13(4 Part I):A356, 1999
55. Pende A, Giacche M, Castigliola L, Contini L, Patrone M, **Port JD**, and Lotti G. Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. *J Hypertension* 17:S141, 1999
56. Blaxall B, Pende A, Wu, S.C., and **Port JD**. Correlation between mRNA stability and affinity of the mRNA binding proteins AUF1 and HuR for A+U-rich mRNAs. AHA Scientific Conference on the Molecular, Cellular, and Integrated Physiological Approaches to the Failing Heart. Abstracts, #94, 1999
57. Communal C, Colucci WS, Sawyer DB, **Port JD**, Wichman SE, Bristow MR, and Singh K. Differential modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases in failing human myocardium. *Circulation* 100:I-199, 1999
58. Pende A, Contini L, Gilberti C, Giachhe M, **Port JD**, and Lotti G. Characterization of the binding of cytosolic RNA-binding proteins to the human AT1 receptor mRNA: any role for the A1166C polymorphism? *J Hypertension* 18(Suppl 2):S75, 2000
59. Perryman MB, **Port JD**, Roden RR, Sederberg JH, and Bristow MR. A comparison of gene expression in failing and non failing human left ventricular tissue. *Circulation* 102:II-449-450, 2000
60. Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeier TJ, Malkinson AM, and **Port JD**. Expression and localization of AUF1/hnRNP D and HuR in hyperplastic and neoplastic lung tissues. *Cold Spring Harbor Symposium on Translational Control*, pg. 51, 2000
61. **Port JD**, Headley V and Tanveer R. Regulation of beta-adrenergic mRNA stability by kinase cascades. 4th West Coast Meeting on mRNA Stability and Translation, Seattle, WA. Scientific Program and Abstracts, pg.36, 2001
62. Contini L, Sallo R, Patrone M, **Port JD**, A. Pende A Lotti G. Caratterizzazione in fibrocellule muscolari lisce vascolari umane di proteine leganti l'mRNA dei recettori AT1 ed AT2. Annual Meeting, Societa Italiana dell'Ipertensione Arteriosa, Roma, IT 2001.
63. Pino I, Cosper, P, Pio R, Dwyer-Nield L, Meyer AM, **Port D**, Montuenga L, and Malkinson AM. Enhanced expression of proteins that regulate alternative splicing of pre-mRNA in mouse lung tumors. *Proceedings of the American Association of Cancer Research*, abstract #842, 2002
64. Lowes BD, Minobe WA Hunter L, Leach S, **Port JD**, Linseman JV, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: characterization of a human model of molecular discovery. *J Cardiac Failure* 8:S13, 2002
65. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, **Port JD**, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered gene expression with improvement in dilated cardiomyopathy. *J Cardiac Failure* 8:S35, 2002
66. Headley V, Tanveer R, Greene S, and **Port JD**. Regulation of beta-adrenergic receptor mRNA stability by MAP kinase cascades. *Cold Spring Harbor Symposium on Translational Control*, pg. 142, 2002
67. Tanveer R, Headley V, Greene S, Cao H, Blackshear PJ, Perryman MB, Fox J, and **Port JD**. Novel proteins that bind to A+U-rich elements of beta-adrenergic receptor mRNAs. *Cold Spring Harbor Symposium on Translational Control*, pg 335, 2002
68. Zerbe L, Peebles K., Pino I, Blaxall B, D. **Port JD**, L. Montuenga L, and Malkinson A. Expression of several pre-mRNA processing proteins increase during pulmonary growth. *Mol Biol Cell* 13:abstract #602, 2002

69. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, **Port JD**, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered gene expression with improvement in dilated cardiomyopathy. *Circulation* 106:II-384, 2002
70. Zerbe L, Pino I, **Port JD**, Montuenga L, and Malkinson A. Increased ASF/SF2 and hnRNP A1 expression in early mouse lung tumorigenesis. Keystone Meeting on RNA Trafficking, Transport and Processing, 2003
71. **Port JD**, Headley V, Tanveer R, Zweifach A, and Greene S. Regulation of beta-adrenergic receptor mRNA stability by MAP kinase cascades. RNA Society Meeting, 2003
72. **Port JD**, Headley V, Tanveer R, Zweifach A, and Greene S. Signaling pathways and AUBPs in the regulation of G-protein-coupled receptor gene expression. First International Meeting on ARE's and AUBP's in mRNA Stability and Translational Control, 2003
73. Chesoni SA, Wilson G, Patel R, Tempesta C, Welsh J, **Port JD**, Maldowney R and Brewer G. Genome-scale identification and cloning of human cardiac mRNA associating with AUF1. Cold Spring Harbor Symposium on Translational Control, 2004
74. Malkinson A, Mason R, Stearman R, Geraci M, **Port JD**, Luis Montuenga L, and Zerbe L. Molecular biotechnologies that detect blood-borne protein biomarkers at early stages of lung cancer in a highly translatable mouse model. Butcher Symposium, UCHSC, 2004
75. **Port JD**, Green S, and Tanveer R. G-protein coupled receptor mRNA stability: factors and signaling pathways. EMBO Workshop on mechanisms and regulation of mRNA turnover. Arolla, Switzerland, 2005
76. David PS, Tanveer R, **Port JD**. FRET-based detection of HuR-AUF1 interaction. RNA Society Annual Meeting, 2006
77. David PS, Tanveer R, **Port JD**. FRET-based detection of HuR-AUF1 interaction. FASEB Summer Research Conference. Post-transcriptional control of gene expression: mechanisms of RNA decay, Snowmass CO, 2006
78. Lowes BD, Gottlieb S, Robertson, O'Connor C, **Port JD**, Liggett S, Bristow MR. Differential Effects of beta-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy. Annual meeting, HFSA, 2006
79. Lowes BD, Gottlieb S, Robertson, O'Connor C, **Port JD**, Thaneemit-Chen S, Liggett S, Bristow MR. Differential Effects of beta-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy. *Circulation* 114:II-443, 2006
80. Nelson B, Morrison J, Nelson P, **Port JD**, Robertson AD, Bristow MR. Beta-blocking agents have codon 389 Arg/Gly genotype specific effects in isolated human heart preparations. JACC, 2006
81. David P, Tanveer R, **Port JD**. Cellular localization of HuR and AUF1. Stress granules or P-bodies? RNA Society Annual Meeting, 2007
82. Bristow MR, and **Port JD**. Improvement in heart failure therapy by genetic targeting. Cold Spring Harbor conference on Pharmacogenomics, Hinxton UK, 2007
83. Sucharov K, Bristow MR, **Port JD**. Regulation and function of MicroRNAs in the failing human heart. Keystone Conference on Pathological and Physiological Regulation of Cardiac Hypertrophy, 2008
84. Walsh R, Farmer R, Kelly M, Nelson P, Morrison J, **Port JD** and Bristow MR. Human myocardial beta₁ 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. HFSA, 2008
85. Kline, KG, Minobe, W, Lowes, B, **Port JD**, Bristow, M, and Wu, CC. (2008) Novel Targeted Proteomic Analysis of the Beta-Adrenergic Signaling Pathway in Human Heart Failure –Poster: NIH Graduate Student Research Festival, Bethesda, MD, 2008

86. Kline, KG, Minobe, W, Lowes, B, **Port, JD**, Bristow, M, and Wu, CC. (2008) Targeted proteomic analysis of the beta-adrenergic receptor signaling pathway in human cardiac biopsies collected over the course of beta-blocker treatment –*Poster: American Society for Mass Spectrometry meeting, Denver, CO, 2008*
87. Mason RP, Kubant R, Jacob RF, Jacoby AM, **Port JD**, Bristow MR, and Malinski T. Effects of bucindolol and its enantiomers on nitric oxide and peroxynitrite release from white, african american and mexican american endothelial cells. HFSA, 2008
88. Mason RP, Kubant R, Jacob RF, Jacoby AM, **Port JD**, Bristow MR, and Malinski T. Effect of the beta3-receptor antagonist SR59230A on bucindolol-induced release of nitric oxide and peroxynitrite from human endothelium. HFSA, 2008
89. Lindenfeld J, Liggett SB, Plehn J, **Port JD**, Fiuzat M, Budhathoki CB, and Bristow MR. Ischemic cardiomyopathy response to bucindolol may be differentially influenced by beta₁ 389 Arg/Gly and alpha_{2c} genotypes. J Cardiac Failure, 14:40-1, 2008
90. Lindenfeld J, Plehn JF, Liggett SB, **Port JD**, Fiuzat M, Robertson AD, Budhathoki CB, Bristow MR. Different patterns of LVEF/remodeling and clinical endpoint effects for bucindolol in beta₁-AR 389 Arg/Gly genotypes. J Cardiac Failure, 14:S77-8, 2008
91. Walsh R, Farmer R, Kelly M, Nelson P, Morrison J, **Port JD**, and Bristow MR. Human myocardial beta₁ 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. HFSA, 2008
92. Sucharov C, Lowes B, Bristow MR, and **Port JD**. miRNA expression profile in patients treated with beta-blocker therapy. Circulation Research, Volume 103. AHA Cardiovascular Basic Sciences Conference 2008. Heart failure: molecular mechanisms and therapeutic targets. 2008
93. Sucharov C, Bristow MR, and **Port JD**. Differential expression of miRNAs in failing versus nonfailing human heart: functional correlates with gene expression programs. FASEB Summer Conference. Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay, Il Ciocco, Italy 2008
94. Sucharov C, Bristow MR, and **Port JD**. Role of miRNAs in heart failure: are the causal and are they potential therapeutic targets. RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, Asheville, NC, 2008
95. Bristow MR, Liggett SB, and **Port JD**. Adrenergic receptor polymorphisms and response to bucindolol in heart failure. Cold Spring Harbor Laboratory Pharmacogenomics Meeting, 2008
96. Gerecht PD and **Port JD**. Intracellular localization and interaction of mRNA binding proteins as detected by FRET. Current Trends in Biomedicine Workshop: RNA-protein interactions in development and cancer. Baeza, Spain, 2009
97. **Port JD**, Lowes BD, Wu C, and Buttrick P. Novel biomarkers predicting responses to heart failure therapeutics. University of Colorado Butcher Symposium, 2009
98. Gerecht PD and **Port JD**. Intracellular localization and FRET-based detection of interactions of RNA binding proteins. RNA Society Annual Meeting, 2010
99. Gerecht PD and **Port JD**. FRET based detection of mRNA binding proteins: localization and specificity. Post-transcriptional control of gene expression: mechanisms of RNA decay, Carefree AZ, 2010
100. Sucharov C, Polk J, Bristow MR and **Port JD**. Expression and function of miRNAs in the nonfailing and failing heart. 4th RNA Stability Meeting: RNA Turnover and Translation. Biological and Pathological Ramifications. Montreal, Canada, 2010

101. Sucharov CC, **Port JD**, and Bristow MR. Temporal expression of miRNAs and mRNAs in a mouse model of cardiomyopathy. 4th RNA Stability Meeting: RNA Turnover and Translation. Biological and Pathological Ramifications. Montreal, Canada, 2010
102. Werahera PN, Jasion EA, La Rosa FG, Lucia MS, Crawford ED, Maroni PD, van Bokhoven A, **Port D**, Sullivan HT, O'Donnell C, Kim FJ, Daily JW. Minimally invasive 16G optical biopsy needle for prostate cancer diagnosis. J Urol 185[4, suppl], e855-856, 2011.
103. **Port JD**, Sucharov C, Robertson AD, and Bristow MR. microRNA expression in heart failure. Experimental Biology, 2012
104. **Port JD**, and Polk J. Interplay of microRNAs and RNA binding proteins. Experimental Biology, 2012
105. Polk J and **Port JD**. Interplay of mRNA binding proteins and miRNAs regulating beta-adrenergic receptor gene expression. Keystone Symposium: Protein-RNA Interactions in Biology and Disease, 2012
106. Polk J and **Port JD**. Interdependency of miRNAs and RNA binding proteins in regulating beta-adrenergic receptor gene expression. FASEB Symposium on Post-transcriptional control of gene expression: mechanisms of mRNA decay, 2012
107. Hinterberg M, Kao D, Karimpour-Fard A, Sucharov C, Hunter LE, **Port JD**, and Bristow MR. Myocardial expression of the microRNA *dre-mir-133a-5p* is associated with improvement in left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy treated with β -blockers. JACC, 2013
108. **Port JD**, Sucharov C, Karimour-Fard A, Hinterberg M, Kao D, Hunter L and Bristow MR. MicroRNAs as Predictive Markers of Disease Progression and Therapeutic Response in Heart Failure. EMBO conference series: Eukaryotic RNA Turnover: From Structural Insights to Diseases, Strasbourg, FR, 2013
109. **Port JD**, Karimpour-Fard A, Kao D, Hinterberg MA, Sucharov C, Lawrence E Hunter, and Bristow MR. Myocardial microRNA expression is a predictor of response to beta-blocker therapy in patients with nonischemic dilated cardiomyopathy. Cold Spring Harbor Laboratory Meeting. Precision Medicine: Personal Genomes & Pharmacogenomics, 2013
110. Walker L, Dockstader K, Slavov D, **Port JD**, and Sucharov C. FXR1G/E and regulation of microRNA function in cardiac disease and differentiation. ISHR, 2014
111. Barhoover M, Albrecht J, **Port JD**, Perry S, and Dufton C. Personalized medicine: prospective patient selection utilizing an ADRB1 genotype assay in the GENETIC-AF clinical trial, HFSA, 2014
112. **Port JD**, Karimpour-Fard A, Kao D, Hinterberg MA, Sucharov C, Hunter LE, and Bristow MR. Topological data analysis of microRNA expression as a predictor of response to beta-blocker therapy in patients with heart failure. RNA Stability 2015 Meeting, Estes Park, CO, 2015
113. **Port JD**, and Sclafani R. Rigor and Reproducibility in biomedical research. NIH TWD Program Director's Meeting, Baltimore, MD, 2017
114. **Port JD**, Sucharov C, Karimpour-Fard, A, Kao D, Nelter B, and Bristow MR. Cardiovascular miRNAs, bipartite: 1. miR's as indicators of heart failure treatment response; 2. The intersection of miR's and ARE-BP's as effectors of beta-adrenergic gene expression. EMBO Conference Series: Eukaryotic RNA Turnover. Oxford, UK, 2017

Presentations/Invited Speaker:

1. Department of Defense, Aberdeen Proving Grounds, MD. Visiting Scientist. 1984
2. Department of Pharmacology, University of Colorado HSC, Invited Speaker. 1991
3. Division of Cardiology, University of Colorado HSC. (Research Seminars and/or Cardiology Grand Rounds) 1991, 92, 93, 94, 95, 96, 06

4. Program in Hormones and Cancer, University of Colorado HSC. 1992, 1996
5. Italian Society of Cardiology, Brescia, Italy. October, Invited Speaker. 1995
6. Department of Pharmacology, University of Colorado HSC, Annual Research Retreat. Invited Speaker. 1995
7. Frontiers of Cardiology, Baylor College of Medicine & Kelsey-Seybold Foundation. Winter Park, CO. Invited Speaker. 1996
8. Wyeth-Ayerst Research, Princeton, N.J., Visiting Scientist. 1996
9. Nexstar Corp., Boulder CO. Invited Speaker. 1997
10. Bristol-Myers, Squibb Pharmaceutical Research Institute, Wallingford CT., Visiting Scientist. 1997
11. Gordon Conference on Catecholamines, Proctor Academy. Invited Speaker. 1997
12. Division of Cardiology, University of Cincinnati, Visiting Professor. 1997
13. Department of Pharmacology, University of Tennessee at Memphis, Visiting Professor. 1998
14. Department of Pharmacology and Toxicology, University of Utah, Visiting Professor. 1998
15. RNA Club, University of Colorado at Boulder. Invited Speaker. 1998
16. Division of Molecular Cardiology, Albert Einstein College of Medicine, Visiting Professor. 1998
17. Institute for Cellular and Molecular Biology, University of Texas at Austin, Visiting Professor. 1998
18. Cardiovascular Biology Group, Boston University, Visiting Professor. 2000
19. Gill Heart Institute, University of Kentucky, Visiting Professor. 2000
20. Mario Negri Institute for Pharmacological Research, Bergamo Italy, Visiting Professor. 2001
21. Department of Internal Medicine, University of Genoa, Italy, Visiting Professor. 2001
22. Symposium on "Catecholamines in Heart Disease", Medical University of Luebeck, Germany. Invited Speaker. 2001
23. Departments of Biochemistry and Internal Medicine, University of Genoa, Italy, Visiting Professor. 2002
24. Department of Experimental Pathology and Oncology, University of Florence, Italy, Visiting Professor, 2002
25. University of Wyoming, Invited Speaker, NIH sponsored symposium on "Possibilities and Pitfalls of Mining DNA Micro-Array Data: From Mice to Men". 2003
26. Department of Cell Biology and Physiology, University of New Mexico, Visiting Professor, 2003
27. First International Meeting on ARE and AUBPs in Translational Control, Florence, Italy, Invited Speaker, Meeting Advisory Board, and Organizing Committee, 2003
28. Annual Meeting of the American Heart Association, Invited Speaker, Symposium on Post-transcriptional mechanisms of gene expression and their role in hypertrophy, 2003
29. Cardiovascular Research Institute, University of South Dakota, Invited Speaker, 2005
30. Department of Pharmacology, University of Wisconsin at Madison, Visiting Professor, 2005
31. EMBO Workshop: Regulation of mRNA Turnover, Arolla, Switzerland, Invited Speaker, 2005
32. Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Visiting Professor, 2005
33. Institute for International Research, Invited speaker, Incorporating Pharmacogenomics in Clinical Studies, Baltimore MD, 2006
34. ASPET/Experimental Biology, Invited speaker, Symposium Chair: Symposium on Post-transcriptional regulation of gene expression, 2007

35. XIX World Congress of the International Society of Heart Research, Bologna, Italy, Invited Speaker, 2007
36. Istituto Nazionale Ricerca sul Cancro (IST), Genoa, Italy, Visiting Professor, 2007
37. Central Labs Partnering, Invited Speaker, 2008
38. CHI's Molecular Medicine Tri-Conference, Invited Speaker, 2008
39. CHI's Genotype and Association Studies conference, San Francisco, CA Invited speaker, 2008
40. FASEB Summer Meeting, Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay, Il Ciocco, Italy, invited talk, 2008
41. RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, Asheville, NC, Meeting Organizer, Invited Speaker, 2008
42. Cold Spring Harbor Laboratories, Adrenergic receptor polymorphisms and response to bucindolol in heart failure. Pharmacogenomics Meeting, Cold Spring Harbor, NY, Invited oral presentation, 2008
43. NIH, Institute on Aging, RNA Biology Group. Invited speaker, 2009
44. ASPET/Experimental Biology, Invited Speaker, Symposium Chair: microRNAs as biological effectors and as pharmacological targets in the cardiovascular system, 2009
45. FASEB Summer Meeting, Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay, Carefree AZ, invited talk, 2010
46. 4th RNA Stability Meeting: RNA Turnover and Translation. Biological and Pathological Ramifications. Symposium Program Committee, Session Chair, Invited Speaker, Montreal, Canada, 2010
47. National Directors of Graduate Studies in Pharmacology and Physiology Meeting, Michigan State University, Invited Speaker, graduate curriculum issues in pharmacology, 2011
48. AAA/Experimental Biology, Invited Speaker, symposium on microRNAs in cardiac development and disease, 2012
49. Department of Pharmacology, University of Colorado SOM, Departmental seminar series, 2012
50. FASEB Summer Meeting, Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay, Steamboat CO, invited talk, 2012
51. University of Colorado School of Medicine, Invited Lecture: A perspective on the 2012 Nobel Prize in Chemistry "for studies of G-protein-coupled receptors", 2013
52. EMBO Conference: Eukaryotic RNA Turnover: From Structural Insights to Diseases, Invited Speaker, IGBMC, Strasbourg, France, 2013
53. RNA Stability 2015: Meeting co-organizer, session chair, invited speaker, Estes Park, CO, 2015
54. EMBO Conference: Eukaryotic RNA Turnover 2017, Invited Speaker, Oxford University, Oxford, UK
55. Colorado College. Presentation to pre-health students. Overview of MSTP and Graduate Programs at CU Anschutz Medical Campus, October 2017
56. CU AMC Campus. Presentation to pre-health students from CSU Pueblo. Overview of MSTP and Graduate Programs at CU Anschutz Medical Campus, March 2018
57. CU AMC Campus, Graduate School T32 Retreat, Panel member, June 2024